Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 10.

Weller, Michael; Tabatabai, G; Kästner, B; Felsberg, J; Steinbach, J P; Wick, A; Schnell, O; Hau, P; Herrlinger, U; Sabel, M C; Wirsching, H G; Ketter, R; Bähr, O; Platten, M; Tonn, J C; Schlegel, U; Marosi, C; Goldbrunner, R; Stupp, R; Homicsko, K; Pichler, J; Nikkhah, G; Meixensberger, J; Vajkoczy, P; Kollias, S; Hüsing, J; Reifenberger, G; Wick, W (2015). MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clinical Cancer Research, 21(9):2057-2064.

Rieger, J; Bähr, O; Maurer, G D; Hattingen, E; Franz, K; Brucker, D; Walenta, S; Kämmerer, U; Coy, J F; Weller, M; Steinbach, J P (2014). ERGO: A pilot study of ketogenic diet in recurrent glioblastoma / Erratum. International Journal of Oncology, 45(6):2605.

Rieger, J; Bähr, O; Maurer, G D; Hattingen, E; Franz, K; Brucker, D; Walenta, S; Kämmerer, U; Coy, J F; Weller, M; Steinbach, J P (2014). ERGO: A pilot study of ketogenic diet in recurrent glioblastoma. International Journal of Oncology, 44(6):1843-1852.

Fischer, S; Ronellenfitsch, M W; Thiepold, A L; Harter, P N; Reichert, S; Kögel, D; Paschke, R; Mittelbronn, M; Weller, M; Steinbach, J P; Fulda, S; Bähr, O (2014). Hypoxia enhances the antiglioma cytotoxicity of b10, a glycosylated derivative of betulinic Acid. PLoS ONE, 9(4):e94921.

Bähr, O; Hermisson, M; Rona, S; Rieger, J; Nussbaumer, S; Körtvelyessy, P; Franz, K; Tatagiba, M; Seifert, V; Weller, M; Steinbach, J P (2012). Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. Acta Neurochirurgica, 154(2):229-235.

Wanka, C; Brucker, D P; Bähr, O; Ronellenfitsch, M; Weller, M; Steinbach, J P; Rieger, J (2012). Synthesis of cytochrome c oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death. Oncogene, 31(33):3764-3776.

Glas, M; Bähr, O; Felsberg, J; Rasch, K; Wiewrodt, D; Schabet, M; Simon, M; Urbach, H; Steinbach, J P; Rieger, J; Fimmers, R; Bamberg, M; Nägele, T; Reifenberger, G; Weller, M; Herrlinger, U (2011). NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Annals of Neurology, 70(3):445-53.

Weiler, M; Hartmann, C; Wiewrodt, D; Herrlinger, U; Gorlia, T; Bähr, O; Meyermann, R; Bamberg, M; Tatagiba, M; von Deimling, A; Weller, M; Wick, W (2010). Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. International Journal of Radiation Oncology, Biology and Physics, 77(3):670-676.

Glas, M; Happold, C; Rieger, J; Wiewrodt, D; Bähr, O; Steinbach, J P; Wick, W; Kortmann, R; Reifenberger, G; Weller, M; Herrlinger, U (2009). Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide. Journal of Clinical Oncology, 27(8):1257-1261.

Bähr, O; Herrlinger, U; Weller, M; Steinbach, J P (2009). Very late relapses in glioblastoma long-term survivors. Journal of Neurology, 256(10):1756-1758.

This list was generated on Tue Nov 21 09:42:15 2017 CET.